passages.id: 745
passages.type: sentence
passages.text: CALGB 8642 randomizes previously untreated metastatic breast cancer patients either to one of several Phase II agents given for up to four cycles and then followed by standard cyclophosphamide-doxorubicin-5-fluorouracil , or to immediate treatment with standard cyclophosphamide-doxorubicin-5-fluorouracil .
entities.id: 746
entities.type: intervention
entities.text: cyclophosphamide-doxorubicin-5-fluorouracil
entities.id: 747
entities.type: intervention
entities.text: cyclophosphamide-doxorubicin-5-fluorouracil
entities.id: 748
entities.type: participant
entities.text: previously untreated metastatic breast cancer patients